NCT07196371 Feasibility of Aerobic Exercise With Blood Flow Restriction Training in People Living With Type 2 Diabetes
| NCT ID | NCT07196371 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of New Brunswick |
| Condition | Type 2 Diabetes |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2026-01-01 |
| Primary Completion | 2028-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2026-01-01 with a primary completion date of 2028-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this trial is to learn if blood flow restriction training with treadmill walking is possible for individuals living with type 2 diabetes. It will also learn about how the blood flow restriction with treadmill walking could improve health. The main questions it aims to answer are: Is 6 weeks of treadmill walking with blood flow restriction reasonable for people with type 2 diabetes to perform? Does treadmill walking with blood flow restriction training help manage type 2 diabetes better than just treadmill walking? Researchers will compare treadmill walking with blood flow restriction to treadmill walking without blood flow restriction to see if blood flow restriction works to manage type 2 diabetes based on fitness and blood sugar levels. Participants will: Perform treadmill walking with or without blood flow restriction for 96 minutes a week for 6 weeks. Visit the lab before and after the exercise for tests and questionnaires.
Eligibility Criteria
Inclusion Criteria: * Diagnosed with type 2 diabetes (5.7% \< HbA1c \< 9.0%) * Not regularly physically active (150 mins moderate-vigorous physical activity per week) Exclusion Criteria: * Musculoskeletal issues preventing exercise training * Unstable medications over the last 3 months * Absolute contraindications to BFR (i.e. peripheral vascular disease) * A self-reported diagnosis of low iron concentrations, anemia, or being treated for these conditions * A diagnosis of any red blood cell-altering condition (i.e., sickle cell anemia, poikilocytosis) * Currently living with any cardiovascular disease, which would impact the ability to participate in exercise safely * Currently prescribed any medication which would impact the ability to use a heart rate monitor to accurately track intensity
Contact & Investigator
Martin Senechal, PhD
PRINCIPAL INVESTIGATOR
Cardiometabolic Exercise & Lifestyle Laboratory, Fredericton, New Brunswick
Frequently Asked Questions
Who can join the NCT07196371 clinical trial?
This trial is open to participants of all sexes, aged 19 Years or older, up to 64 Years, studying Type 2 Diabetes. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07196371 currently recruiting?
Yes, NCT07196371 is actively recruiting participants. Contact the research team at martin.senechal@unb.ca for enrollment information.
Where is the NCT07196371 trial being conducted?
This trial is being conducted at Okanagan, Canada, Fredericton, Canada, Guelph, Canada.
Who is sponsoring the NCT07196371 clinical trial?
NCT07196371 is sponsored by University of New Brunswick. The principal investigator is Martin Senechal, PhD at Cardiometabolic Exercise & Lifestyle Laboratory, Fredericton, New Brunswick. The trial plans to enroll 60 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.